Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
about
sameAs
Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug ResistanceABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansStructural basis of drug resistance for the V82A mutant of HIV-1 proteinaseIn vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinationsAntiviral properties of aminodiol inhibitors against human immunodeficiency virus and proteaseABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseCharacterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitorL-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitorSelection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral proteaseCGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activityIn vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 proteaseIn vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatineEfficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitroTargets of a protease inhibitor, KNI-272, in HIV-1-infected cells.Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Antiviral therapy for human immunodeficiency virus infectionsPreclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 proteaseHuman immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral proteasePartial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.Proteases and protease inhibitors in infectious diseases.Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
P2860
Q27657395-93C34073-E285-4EDC-A4B7-3A3DCB77B302Q27729982-94835974-DC5E-47AE-915B-D1FA7FA9F185Q27730261-12D22593-0292-49F8-90FD-1D2A218A120AQ28318476-EBBC24C8-8CF6-46EB-BDBE-9D72112425C8Q28368090-05CD5766-F256-4A60-A718-874EF4A3F2F3Q28369297-81985B89-60D5-4FE6-AD5A-0F1F479B6F82Q28369516-8695F628-A7B8-4101-80AC-1565ED31B8B6Q28369664-FA568890-B2F9-4FF9-9396-6D612E98C52AQ28378274-5232A99A-3EB9-4DDA-B7B2-B09A8DC1D60EQ28378396-F97A521C-EFCA-4F9B-B321-885517D97D20Q28378566-97FC3BA3-D4FF-43CB-8B05-F5D31C129B2BQ28378709-B2D583AA-573F-4197-B0C0-14BD5E055E37Q28378785-6615050A-497E-49C7-B6C1-ED6BAA8F37B1Q31912488-93F272A2-6766-48DA-9394-E8C5DCFFF723Q34046931-409175C2-4A29-4D98-B181-A6F2719AC15FQ35125088-B4F8DC36-85F3-455E-8A78-7FA585BCA578Q35134071-65C4F6FD-1639-448B-B5EF-BAFF33777751Q35174341-3C6E3CBF-C668-4738-940F-CBA8B7DCAC2CQ35237575-98436037-2085-4D74-AF42-20A87CAE0D7DQ35366050-5270BC76-E91F-44C5-B256-19A51243E8C6Q35807808-5DB0914D-FDBF-41D8-BD78-88092A765BF6Q35823493-2198C9CA-5843-49D0-B665-F56611EBE2E7Q35870149-D85B0A1A-6D19-46E8-8B71-F543E02C6A33Q35876343-806E8FC0-3991-4FDB-989C-44F304BAFA9FQ36650046-07C4DB77-0EDE-4DB2-8DE4-47D4AE19C728Q37366303-2C611391-AA17-47DA-BB59-14F3B418CD72Q37980084-957AEEAD-0CFF-4103-B997-A34B34E148F9Q39780160-D3A0BEE5-0C7F-4021-AE74-FAAEA12C8633Q39875987-62839129-9C38-4FB2-9333-620588E99E52Q39876857-601442B2-EC49-4E94-8C1A-AA89DB1EEF90Q40770222-DFF40CD5-D255-4F0B-8410-5255C451D076Q42545682-32C9DCC4-2285-46CF-ABF6-7DB78B0BADB8Q47576680-9AFFD59F-496D-448D-88F0-D501F6B69BDDQ54257557-8F12180A-6723-4725-BAC7-FF06B722AB18
P2860
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
description
1991 nî lūn-bûn
@nan
1991 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@ast
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@en
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@nl
type
label
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@ast
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@en
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@nl
prefLabel
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@ast
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@en
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@nl
P2093
P2860
P356
P1476
Antiviral and pharmacokinetic ...... ficiency virus type 1 protease
@en
P2093
D W Norbeck
L Codacovi
M F Knigge
S Vasavanonda
W E Kohlbrenner
P2860
P304
P356
10.1128/AAC.35.11.2209
P407
P577
1991-11-01T00:00:00Z